ABBOTT LABORATORIES — Director's Dealing 2021

Jul 6, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-07-01

Reporting Person: Calamari Christopher J. (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	12156	Direct
Common shares without par value	30193	Indirect
Common shares without par value	100	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$59.94	2028-02-15	Common Shares (51559)		Direct
Option (right to buy)	$75.90	2029-02-21	Common Shares (42009)		Direct
Option (right to buy)	$87.72	2030-02-20	Common Shares (37081)		Direct
Option (right to buy)	$124.04	2031-02-18	Common Shares (27840)		Direct

Footnotes

F1: Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019, 17,187 on February 16, 2020 and 17,186 on February 16, 2021.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,003 on February 22, 2020 and 14,003 on February 22, 2021, and an increment of 14,003 becomes exercisable on February 22, 2022.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 12,360 on February 21, 2021 and annual increments of 12,360 and 12,361 become exercisable on February 21, 2022 and February 21, 2023, respectively.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,280 on February 19, 2022, 9,280 on February 19, 2023, and 9,280 on February 19, 2024.